Resident's Forum
Rituximab: Revolutionizing the Treatment of Pemphigus
FR-Rituximab, una revolución en el tratamiento del pénfigo
D. Morgado-Carrasco, P. Giavedoni, X. Fustà-Novell, P. Iranzo
Corresponding author
Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain
Read
5661
Timeswas read the article
2156
Total PDF
3505
Total HTML
Share statistics
array:24 [ "pii" => "S1578219017304286" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.12.015" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "1747" "copyright" => "Elsevier España, S.L.U. and AEDV" "copyrightAnyo" => "2017" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2018;109:177-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 110 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 67 "PDF" => 37 ] ] "Traduccion" => array:1 [ "es" => array:19 [ "pii" => "S0001731017303757" "issn" => "00017310" "doi" => "10.1016/j.ad.2017.06.010" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "1747" "copyright" => "AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2018;109:177-8" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 472 "formatos" => array:2 [ "HTML" => 258 "PDF" => 214 ] ] "es" => array:10 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Foro de Residentes</span>" "titulo" => "FR-Rituximab, una revolución en el tratamiento del pénfigo" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "177" "paginaFinal" => "178" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "RF-Rituximab: Revolutionizing the Treatment of Pemphigus" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "D. Morgado-Carrasco, P. Giavedoni, X. Fustà-Novell, P. Iranzo" "autores" => array:4 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Giavedoni" ] 2 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 3 => array:2 [ "nombre" => "P." "apellidos" => "Iranzo" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "S1578219017304286" "doi" => "10.1016/j.adengl.2017.12.015" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017304286?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017303757?idApp=UINPBA000044" "url" => "/00017310/0000010900000002/v1_201803020417/S0001731017303757/v1_201803020417/es/main.assets" ] ] "itemSiguiente" => array:19 [ "pii" => "S1578219017304304" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.12.017" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "1656" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "article" "crossmark" => 1 "subdocumento" => "sco" "cita" => "Actas Dermosifiliogr. 2018;109:179" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 108 "formatos" => array:3 [ "EPUB" => 9 "HTML" => 79 "PDF" => 20 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Images in Dermatology</span>" "titulo" => "Viscerocutaneous Loxoscelism" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "179" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Loxoscelismo cutáneo-visceral" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 1179 "Ancho" => 1667 "Tamanyo" => 205199 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "R. Cullen, P. Hasbún, M.P. Piquer" "autores" => array:3 [ 0 => array:2 [ "nombre" => "R." "apellidos" => "Cullen" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Hasbún" ] 2 => array:2 [ "nombre" => "M.P." "apellidos" => "Piquer" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731017301746" "doi" => "10.1016/j.ad.2016.12.020" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017301746?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017304304?idApp=UINPBA000044" "url" => "/15782190/0000010900000002/v1_201803020443/S1578219017304304/v1_201803020443/en/main.assets" ] "itemAnterior" => array:19 [ "pii" => "S1578219017304274" "issn" => "15782190" "doi" => "10.1016/j.adengl.2017.12.014" "estado" => "S300" "fechaPublicacion" => "2018-03-01" "aid" => "1640" "copyright" => "Elsevier España, S.L.U. and AEDV" "documento" => "simple-article" "crossmark" => 1 "subdocumento" => "crp" "cita" => "Actas Dermosifiliogr. 2018;109:175-6" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 95 "formatos" => array:3 [ "EPUB" => 6 "HTML" => 70 "PDF" => 19 ] ] "en" => array:11 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Case for Diagnosis</span>" "titulo" => "Vasculitis With Lesions on the Scalp as the Only Cutaneous Manifestation" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "175" "paginaFinal" => "176" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Vasculitis con lesiones en cuero cabelludo como única manifestación cutánea" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "resumenGrafico" => array:2 [ "original" => 0 "multimedia" => array:6 [ "identificador" => "fig0005" "etiqueta" => "Figure 1" "tipo" => "MULTIMEDIAFIGURA" "mostrarFloat" => true "mostrarDisplay" => false "figura" => array:1 [ 0 => array:4 [ "imagen" => "gr1.jpeg" "Alto" => 703 "Ancho" => 1250 "Tamanyo" => 149810 ] ] ] ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "F.C. Benavente Villegas, J.M. Sánchez Motilla, N. Rausell Fontestad" "autores" => array:3 [ 0 => array:2 [ "nombre" => "F.C. Benavente" "apellidos" => "Villegas" ] 1 => array:2 [ "nombre" => "J.M. Sánchez" "apellidos" => "Motilla" ] 2 => array:2 [ "nombre" => "N. Rausell" "apellidos" => "Fontestad" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "S0001731017301278" "doi" => "10.1016/j.ad.2016.08.010" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S0001731017301278?idApp=UINPBA000044" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017304274?idApp=UINPBA000044" "url" => "/15782190/0000010900000002/v1_201803020443/S1578219017304274/v1_201803020443/en/main.assets" ] "en" => array:14 [ "idiomaDefecto" => true "cabecera" => "<span class="elsevierStyleTextfn">Resident's Forum</span>" "titulo" => "Rituximab: Revolutionizing the Treatment of Pemphigus" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "177" "paginaFinal" => "178" ] ] "autores" => array:1 [ 0 => array:4 [ "autoresLista" => "D. Morgado-Carrasco, P. Giavedoni, X. Fustà-Novell, P. Iranzo" "autores" => array:4 [ 0 => array:2 [ "nombre" => "D." "apellidos" => "Morgado-Carrasco" ] 1 => array:2 [ "nombre" => "P." "apellidos" => "Giavedoni" ] 2 => array:2 [ "nombre" => "X." "apellidos" => "Fustà-Novell" ] 3 => array:4 [ "nombre" => "P." "apellidos" => "Iranzo" "email" => array:1 [ 0 => "piranzo@clinic.cat" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">*</span>" "identificador" => "cor0005" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:2 [ "entidad" => "Dermatology Department, Hospital Clínic de Barcelona, Barcelona, Spain" "identificador" => "aff0005" ] ] "correspondencia" => array:1 [ 0 => array:3 [ "identificador" => "cor0005" "etiqueta" => "⁎" "correspondencia" => "Corresponding author." ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "FR-Rituximab, una revolución en el tratamiento del pénfigo" ] ] "textoCompleto" => "<span class="elsevierStyleSections"><p id="par0005" class="elsevierStylePara elsevierViewall">Pemphigus is an autoimmune disease that causes blisters and erosions and is characterized by autoantibodies to desmogleins. Its prognosis was dismal until 1959, when the introduction of corticosteroids revolutionized treatment and drastically reduced associated deaths.<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a> Corticosteroids have been the first-line treatment for pemphigus ever since. Long-term high-dose corticosteroid therapy achieves high remission rates, but comes with considerable adverse effects. Immunosuppressive drugs and immunomodulators are often used as corticosteroid-sparing agents in an attempt to reduce these effects, but there is limited evidence on their effectiveness (<a class="elsevierStyleCrossRef" href="#tbl0005">Table 1</a>).<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a></p><elsevierMultimedia ident="tbl0005"></elsevierMultimedia><p id="par0010" class="elsevierStylePara elsevierViewall">Rituximab (RTX) is an anti-CD20 monoclonal antibody that has been used off-label to treat pemphigus for several decades. It is used particularly to treat patients with refractory disease or who are unable to tolerate conventional treatment.<a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">3</span></a> The results of the first multicenter, prospective, open-label, randomized trial comparing the efficacy of RTX combined with low-dose prednisone (RTX-LDPRD) with that of long-term high-dose prednisone as monotherapy (HD-PDN) were recently published.<a class="elsevierStyleCrossRef" href="#bib0040"><span class="elsevierStyleSup">4</span></a> The study included 90 adults recently diagnosed with untreated pemphigus vulgaris or pemphigus foliaceus. The RTX-LDPRD group received 1<span class="elsevierStyleHsp" style=""></span>g of RTX on days 0 and 14, followed by 500<span class="elsevierStyleHsp" style=""></span>mg at months 12 and 18 together with 0.5 or 1<span class="elsevierStyleHsp" style=""></span>mg/kg/d of prednisone tapered over 3 months for moderate disease or 6 months for severe disease. The HD-PRD group received 1 or 1.5<span class="elsevierStyleHsp" style=""></span>mg/kg/d of prednisone tapered over 12 or 18 months (for moderate and severe disease, respectively). The follow-up period for both groups was 36 months. Significant results were observed at 24 months: 89% (41/46) of the patients in the RTX-LDPRD group achieved complete remission without treatment (CR-WT) versus 34% (15/44) of those in the HD-PRD group (relative risk, 2.61; 95% CI, 1.71-3.99; <span class="elsevierStyleItalic">p</span><span class="elsevierStyleHsp" style=""></span><<span class="elsevierStyleHsp" style=""></span>.0001). Time to CR-WT was shorter in the RTX-LDPRD group (277 vs. 677 days) and these patients also experienced longer disease-free periods (466 vs. 62 days, representing a 7-fold difference). The cumulative dose of corticosteroids was 3 times lower in patients treated with RTX-LDPRD, who also had fewer serious adverse effects (27 events in 16 patients vs. 53 events in 29 patients). There were no differences in number of infections. The most common adverse effects were endocrine, muscular, and bone disorders. The recurrence rate in the first 24 months was 24% in the RTX-LDPRD group and 45% in the HD-PRD group. Just 1 of the patients in the RTX-LDPRD group who achieved CR-WT at month 24 experienced recurrence over the next 12 months. In brief, patients treated with RTX combined with low-dose corticosteroids responded better, faster, and for longer and also had fewer recurrences and adverse effects. Treatment cost per patient was 5500 Euro more expensive in the RTX-LDPRD group but this difference is of little significance if we consider the associated reductions in adverse effects, work absenteeism, and indirect health costs. The results of this trial suggest that RTX could revolutionize the treatment of pemphigus, replacing corticosteroid therapy as the first-line treatment option.</p></span>" "pdfFichero" => "main.pdf" "tienePdf" => true "PalabrasClave" => array:1 [ "en" => array:1 [ 0 => array:4 [ "clase" => "keyword" "titulo" => "Keywords" "identificador" => "xpalclavsec957577" "palabras" => array:4 [ 0 => "Rituximab" 1 => "RITUX 3" 2 => "Pemphigus" 3 => "Corticosteroids" ] ] ] ] "NotaPie" => array:1 [ 0 => array:2 [ "etiqueta" => "☆" "nota" => "<p class="elsevierStyleNotepara" id="npar0005">Please cite this article as: Morgado-Carrasco D, Giavedoni P, Fustà-Novell X, Iranzo P. FR-Rituximab, una revolución en el tratamiento del pénfigo. Actas Dermosifiliogr. 2018;109:177–178.</p>" ] ] "multimedia" => array:1 [ 0 => array:8 [ "identificador" => "tbl0005" "etiqueta" => "Table 1" "tipo" => "MULTIMEDIATABLA" "mostrarFloat" => true "mostrarDisplay" => false "detalles" => array:1 [ 0 => array:3 [ "identificador" => "at1" "detalle" => "Table " "rol" => "short" ] ] "tabla" => array:2 [ "leyenda" => "<p id="spar0010" class="elsevierStyleSimplePara elsevierViewall">Source: Bystryn et al.,<a class="elsevierStyleCrossRef" href="#bib0025"><span class="elsevierStyleSup">1</span></a> Atzmony et al.,<a class="elsevierStyleCrossRef" href="#bib0030"><span class="elsevierStyleSup">2</span></a> and Wang et al.<span class="elsevierStyleSup">.</span><a class="elsevierStyleCrossRef" href="#bib0035"><span class="elsevierStyleSup">3</span></a></p>" "tablatextoimagen" => array:1 [ 0 => array:2 [ "tabla" => array:1 [ 0 => """ <table border="0" frame="\n \t\t\t\t\tvoid\n \t\t\t\t" class=""><tbody title="tbody"><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">1. Untreated pemphigus has a mortality rate of ><span class="elsevierStyleHsp" style=""></span>70%. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">2. The mortality rate in patients treated with corticosteroids is <<span class="elsevierStyleHsp" style=""></span>10%. However, mortality is more closely linked to treatment side effects than to the disease. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">3. Adjuvant therapy with immunosuppressive drugs reduces recurrence but no clear evidence has been found for its association with higher complete response rates or fewer adverse effects. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">4. Intravenous immunoglobulin therapy can increase complete clinical response rates. \t\t\t\t\t\t\n \t\t\t\t</td></tr><tr title="table-row"><td class="td-with-role" title="table-entry ; entry_with_role_rowhead " align="left" valign="top">5. Rituximab has achieved complete clinical response rates of ><span class="elsevierStyleHsp" style=""></span>75% in clinical trials and case series. \t\t\t\t\t\t\n \t\t\t\t</td></tr></tbody></table> """ ] "imagenFichero" => array:1 [ 0 => "xTab1685933.png" ] ] ] ] "descripcion" => array:1 [ "en" => "<p id="spar0005" class="elsevierStyleSimplePara elsevierViewall">Key Points in the Treatment of Pemphigus.</p>" ] ] ] "bibliografia" => array:2 [ "titulo" => "References" "seccion" => array:1 [ 0 => array:2 [ "identificador" => "bibs0015" "bibliografiaReferencia" => array:4 [ 0 => array:3 [ "identificador" => "bib0025" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The adjuvant therapy of pemphigus. An update" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:2 [ 0 => "J.C. Bystryn" 1 => "N.M. Steinman" ] ] ] ] ] "host" => array:1 [ 0 => array:1 [ "Revista" => array:6 [ "tituloSerie" => "Arch Dermatol" "fecha" => "1996" "volumen" => "132" "paginaInicial" => "203" "paginaFinal" => "212" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/8629830" "web" => "Medline" ] ] ] ] ] ] ] ] 1 => array:3 [ "identificador" => "bib0030" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "The role of adjuvant therapy in pemphigus: A systematic review and meta-analysis" "autores" => array:1 [ 0 => array:2 [ "etal" => true "autores" => array:6 [ 0 => "L. Atzmony" 1 => "E. Hodak" 2 => "Y.A. Leshem" 3 => "O. Rosenbaum" 4 => "M. Gdalevich" 5 => "G.J. Anhalt" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/j.jaad.2015.04.038" "Revista" => array:6 [ "tituloSerie" => "J Am Acad Dermatol" "fecha" => "2015" "volumen" => "73" "paginaInicial" => "264" "paginaFinal" => "271" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/26088689" "web" => "Medline" ] ] ] ] ] ] ] ] 2 => array:3 [ "identificador" => "bib0035" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "Efficacy of rituximab for pemphigus: A systematic review and meta-analysis of different regimens" "autores" => array:1 [ 0 => array:2 [ "etal" => false "autores" => array:4 [ 0 => "H.H. Wang" 1 => "C.W. Liu" 2 => "Y.C. Li" 3 => "Y.C. Huang" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.2340/00015555-2116" "Revista" => array:6 [ "tituloSerie" => "Acta Derm Venereol" "fecha" => "2015" "volumen" => "95" "paginaInicial" => "928" "paginaFinal" => "932" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/25881672" "web" => "Medline" ] ] ] ] ] ] ] ] 3 => array:3 [ "identificador" => "bib0040" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:2 [ "contribucion" => array:1 [ 0 => array:2 [ "titulo" => "First-line rituximab combined with short-term prednisone versus prednisone alone for the treatment of pemphigus (Ritux 3): A prospective, multicentre, parallel-group, open-label randomised trial" "autores" => array:1 [ 0 => array:3 [ "colaboracion" => "French study group on autoimmune bullous skin diseases" "etal" => true "autores" => array:6 [ 0 => "P. Joly" 1 => "M. Maho-Vaillant" 2 => "C. Prost-Squarcioni" 3 => "V. Hebert" 4 => "E. Houivet" 5 => "S. Calbo" ] ] ] ] ] "host" => array:1 [ 0 => array:2 [ "doi" => "10.1016/S0140-6736(17)30070-3" "Revista" => array:6 [ "tituloSerie" => "Lancet" "fecha" => "2017" "volumen" => "389" "paginaInicial" => "2031" "paginaFinal" => "2040" "link" => array:1 [ 0 => array:2 [ "url" => "https://www.ncbi.nlm.nih.gov/pubmed/28342637" "web" => "Medline" ] ] ] ] ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/15782190/0000010900000002/v1_201803020443/S1578219017304286/v1_201803020443/en/main.assets" "Apartado" => array:4 [ "identificador" => "34945" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Resident's Forum" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/15782190/0000010900000002/v1_201803020443/S1578219017304286/v1_201803020443/en/main.pdf?idApp=UINPBA000044&text.app=https://actasdermo.org/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/S1578219017304286?idApp=UINPBA000044" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 9 | 11 | 20 |
| 2024 October | 91 | 48 | 139 |
| 2024 September | 122 | 26 | 148 |
| 2024 August | 120 | 62 | 182 |
| 2024 July | 99 | 34 | 133 |
| 2024 June | 97 | 21 | 118 |
| 2024 May | 80 | 41 | 121 |
| 2024 April | 91 | 26 | 117 |
| 2024 March | 89 | 27 | 116 |
| 2024 February | 85 | 31 | 116 |
| 2024 January | 71 | 27 | 98 |
| 2023 December | 77 | 22 | 99 |
| 2023 November | 79 | 26 | 105 |
| 2023 October | 84 | 33 | 117 |
| 2023 September | 64 | 26 | 90 |
| 2023 August | 39 | 13 | 52 |
| 2023 July | 86 | 25 | 111 |
| 2023 June | 72 | 22 | 94 |
| 2023 May | 54 | 27 | 81 |
| 2023 April | 71 | 20 | 91 |
| 2023 March | 41 | 26 | 67 |
| 2023 February | 42 | 27 | 69 |
| 2023 January | 41 | 29 | 70 |
| 2022 December | 61 | 41 | 102 |
| 2022 November | 27 | 27 | 54 |
| 2022 October | 33 | 20 | 53 |
| 2022 September | 30 | 38 | 68 |
| 2022 August | 25 | 25 | 50 |
| 2022 July | 21 | 48 | 69 |
| 2022 June | 21 | 19 | 40 |
| 2022 May | 45 | 48 | 93 |
| 2022 April | 75 | 62 | 137 |
| 2022 March | 77 | 69 | 146 |
| 2022 February | 71 | 39 | 110 |
| 2022 January | 81 | 48 | 129 |
| 2021 December | 40 | 45 | 85 |
| 2021 November | 60 | 61 | 121 |
| 2021 October | 62 | 77 | 139 |
| 2021 September | 47 | 46 | 93 |
| 2021 August | 42 | 46 | 88 |
| 2021 July | 31 | 40 | 71 |
| 2021 June | 46 | 63 | 109 |
| 2021 May | 62 | 74 | 136 |
| 2021 April | 101 | 99 | 200 |
| 2021 March | 94 | 45 | 139 |
| 2021 February | 90 | 46 | 136 |
| 2021 January | 69 | 44 | 113 |
| 2020 December | 73 | 57 | 130 |
| 2020 November | 50 | 40 | 90 |
| 2020 October | 40 | 27 | 67 |
| 2020 September | 46 | 24 | 70 |
| 2020 August | 50 | 28 | 78 |
| 2020 July | 38 | 38 | 76 |
| 2020 June | 46 | 29 | 75 |
| 2020 May | 23 | 22 | 45 |
| 2020 April | 32 | 14 | 46 |
| 2020 March | 24 | 20 | 44 |
| 2020 February | 3 | 0 | 3 |
| 2020 January | 4 | 0 | 4 |
| 2019 December | 8 | 0 | 8 |
| 2019 November | 3 | 0 | 3 |
| 2019 September | 10 | 0 | 10 |
| 2019 August | 4 | 0 | 4 |
| 2019 July | 4 | 0 | 4 |
| 2019 June | 4 | 0 | 4 |
| 2019 May | 7 | 1 | 8 |
| 2019 April | 2 | 0 | 2 |
| 2019 March | 2 | 0 | 2 |
| 2019 February | 2 | 0 | 2 |
| 2018 December | 4 | 0 | 4 |
| 2018 November | 2 | 0 | 2 |
| 2018 September | 3 | 0 | 3 |
| 2018 February | 4 | 26 | 30 |
| 2018 January | 2 | 10 | 12 |
Show all
